Health Canada says AstraZeneca vaccine is safe after investigating blood clot reports - Global News | Canada News Media
Connect with us

Business

Health Canada says AstraZeneca vaccine is safe after investigating blood clot reports – Global News

Published

 on


Health Canada on Thursday said the benefits of AstraZeneca’s COVID-19 vaccine “continue to outweigh the risks” after investigating reported blood clots in several countries, and encouraged Canadians to receive it if offered.

The agency said an assessment of available data on the reports out of Europe determined no link between the vaccine and an increase in the overall risk of blood clots. Health Canada stressed that the reports themselves were rare, and suggested blood clots “can also be due to COVID-19” itself.

Read more:
EU regulator declares AstraZeneca vaccine safe and effective for continued use

While Health Canada did find one report of a stroke that occurred in an individual who was inoculated with the AstraZeneca vaccine, it was found not to be related to the shot.

“Health Canada will continue to work with international regulators and review data and evidence as it becomes available, including as it pertains to these rare events,” a statement from the department read.

Story continues below advertisement

It added that officials are working with AstraZeneca to ensure health-care professionals and Canadians have the safety information they need.






1:56
U.S. to send Oxford-AstraZeneca vaccine doses to Canada


U.S. to send Oxford-AstraZeneca vaccine doses to Canada

Earlier Thursday, the European Medicines Agency announced it had come to the same conclusion about the vaccine’s safety. Yet the drug watchdog’s director Emer Cooke said the agency could not definitively rule out a link to blood clot incidents and the vaccine in its investigation into 30 cases of a rare blood clotting condition.

The agency had been under growing pressure to clear up safety concerns after a small number of reports in recent weeks of bleeding, blood clots and low platelet counts in people who have received the shot.

The agency’s review, covering 5 million people, included 30 cases of unusual blood disorders in people in the European Economic Area (EEA), which links 30 European countries.

Story continues below advertisement

Read more:
Science says AstraZeneca’s COVID-19 vaccine is safe. But will that ease concerns?

At least 13 European countries, including France, Germany and Italy, have stopped administering the shot pending the review, the latest blow to the bloc’s faltering inoculation campaign.

AstraZeneca has also been scrutinized for not providing sufficient data on the vaccine’s efficacy among seniors, prompting Canada and other countries to warn the shot should not be given to people over the age of 65.

Canada’s National Advisory Committee on Immunization reversed its stance earlier this week, announcing that the vaccine was safe for seniors.

The committee cited “real-world evidence” that demonstrates the vaccine is safe and effective in older adults, particularly against severe illness from COVID-19 and hospitalization.






4:02
COVID-19: Spain, Germany and France to resume use of AstraZeneca vaccine as UK PM Johnson to get the jab


COVID-19: Spain, Germany and France to resume use of AstraZeneca vaccine as UK PM Johnson to get the jab

Still, if there is a choice, NACI says mRNA vaccines — like Pfizer’s and Moderna’s — should be prioritized for use on seniors, but that it no longer recommends against using AstraZeneca for anyone over the age of 65.

Story continues below advertisement

Health Canada approved the AstraZeneca vaccine for use in anyone 18 years or older in late February. It became the third COVID-19 shot green-lit in Canada, joining vaccines from Pfizer-BioNTech and Moderna.

Canada’s initial 500,000 doses of the AstraZeneca COVID-19 vaccine have been manufactured by the Serum Institute in India. In total, two million doses will arrive in the country from that agreement.

The initial doses delivered last week have now been spoken for. Another 20 million doses already secured with AstraZeneca aren’t expected until sometime in April, which leaves provinces with time to reconsider how they will roll out the next batch and to whom.

— With files from Hannah Jackson, Rachael D’Amore and Reuters

© 2021 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version